Drugs / DJI136
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07564401 | Jun 2026 → Mar 2031 expected | small cell lung carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DJI136 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07564401 ↗ |
| Modality | Cell therapy | “DJI136 (a CAR-T therapy)” NCT07564401 ↗ |
| Route | Intravenous | “administered by intravenous (i.v.) infusion.” NCT07564401 ↗ |
| Target | DLL3 | “DLL3 targeted CAR-T therapy” NCT07564401 ↗ |